Video Rating: 1 / 5
SeniorGumBoy @CraigChung After having some trouble in the bedroom department. Mr Jones goes to see DR Dagga since he is the daggering expert. He ends up fin…
Chicago, IL (PRWEB) September 30, 2014
NuMale Medical Center, a nationwide leader in mens sexual dysfunction and enhancement, announced today that its Chicago mens health clinic has exceeded expectations, treating men from diverse backgrounds, ages, and geographic areas. Since opening its doors in March of 2014, NuMales Chicago clinic has helped patients suffering from erectile dysfunction (ED), low libido, low testosterone (low-T), and many other medical issues.
Run by Medical Director Dr. Todd Arbiture, D.O., NuMale Medical Center has successfully treated thousands of patients from the Chicago area and all over the Midwest. NuMales unique, science-based approach to mens sexual dysfunction and enhancement has attracted patients of all ages and backgrounds who suffer from these conditions.
Each patient at NuMale Medical Center receives a confidential, comprehensive medical evaluation. After a thorough consultation, NuMales expert physicians create a custom-tailored action plan for each patient. This ensures that every individual receives the safest, most effective treatment possible for his medical history and specific needs.
NuMales industry-leading medical staff regularly helps patients suffering from premature ejaculation, low sex drive, and even hair loss. Using FDA-approved treatments, including the PriapusTM procedure, NuMales doctors achieve a 98 percent success rate in treating ED. This allows NuMale to offer a 100 percent money-back guarantee on ED consultations for new patients.
NuMales Chicago office has helped thousands of patients suffering from sexual dysfunction and other issues, said Medical Director Dr. Todd Arbiture, D.O. We have worked hard to create a comfortable environment for men to discuss these important health-related topics, and I am incredibly proud of the response we have seen. NuMales science-based approach sets us apart from other clinics, and we work every day to treat our patients overall well-being while restoring their confidence and improving their relationships.
NuMale Medical Center is located at 4711 Golf Rd #1050, Skokie, IL 60076. Conveniently located just off I-94 near the Westfield Old Orchard Mall, NuMales office features a no-waiting policy. For more information about NuMale, or to schedule an appointment, please call NuMale Medical Center at 847-354-4383 or visit http://www.numale.com
About NuMale Medical Center
NuMale Medical Center is a leading national provider of customized, comprehensive treatment for male sexual dysfunction and enhancement. NuMale helps men suffering from erectile dysfunction (ED), low testosterone (Low-T), premature ejaculation (PE) and low sex drive, utilizing a wide range of the most highly-respected, FDA-approved treatments and therapies including bio-identical hormone replacement and the Priapus shot. Founded and led by accomplished physician Dr. Christopher Asandra M.D., NuMale Medical Center has expanded rapidly in its first year, with six nationwide facilities and many more to come. Learn more at numale.com and follow the company on Facebook, Twitter and LinkedIn.
How to Rekindle Your Sexual Desire
More than half of men and two-thirds of women experience sexual health problems by midlife. But in contrast to the myriad of over two dozen approved medical treatments for sexual dysfunction in men, not one medical treatment has been approved for use …
Read more on Huffington Post Canada
Jim Warren: Our failure to communicate
Imagine a shiny SUV that tended to explode. Or erectile dysfunction pills that gave your toes gangrene. They wouldn't be terribly marketable, right? A similar burden would seem to be shared by the peddlers of the world's most odious brand: ISIS.
Read more on New York Daily News
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA …
SPEDRA is now the first and only erectile dysfunction (ED) medication approved in Europe that is indicated to be taken as needed approximately 15 to 30 minutes before sexual activity. "We are pleased with the EC decision to approve the label amendment …
Read more on MarketWatch
Green Bay, WI (PRWEB) October 27, 2014
NuMale Medical Center announced the opening of a new facility in Green Bay today. This is NuMales second office in Wisconsin and seventh nationwide; the company launched in Milwaukee and rapidly expanded to other states as demand for its unique services surged.
Like all of NuMales state-of-the-art clinics, the Green Bay location will embody the companys commitment to employing a safe, comprehensive approach to treating issues facing men of all ages and backgrounds. Since its founding in 2013, NuMale Medical Center has helped tens of thousands of men suffering from sexual dysfunction and aging-related conditions.
Led by Chief Medical Officer Dr. Christopher Asandra, M.D., NuMales expert physicians provide each patient with a comprehensive, confidential medical evaluation and consultation on their first visit. After this evaluation, NuMales medical team customizes the most appropriate and effective treatment plan to address each patients individual needs.
NuMale Medical Centers industry-leading doctors help patients suffering from erectile dysfunction (E.D.), premature ejaculation, and low sex drive. Using FDA-approved treatments, NuMales doctors achieve a 98 percent success rate in treating E.D. By employing innovative and effective treatment methods, including the Priapus (TM) procedure, NuMale is able to offer a 100 percent money back guarantee on its E.D. consultation for new patients.
NuMale is also the first and only clinic in Wisconsin to offer NeoGraft
There are many people that believe that active cyclists are at a higher risk for developing erectile dysfunction, prostate cancer, and infertility. Is there …
Video Rating: 4 / 5
Albany, New York (PRWEB) September 11, 2014
According to a new market report published by Transparency Market Research “Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) – Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 – 2019″, the global insulin market was valued at USD 19.99 billion in 2012 and is expected to grow at a CAGR of 6.1% from 2013 to 2019 to reach USD 32.24 billion in 2019.
Browse the full Global and China Insulin Market Report with TOC: http://www.transparencymarketresearch.com/insulin-market.html
Rising prevalence of diabetes is one of the serious healthcare concerns on a global level. Insulin is a hormone secreted by pancreas to absorb the blood sugar. However, in diabetes, it is either not possible for the body to secrete insulin (type-1) or to utilize secreted insulin to metabolize glucose (type-2). Insulin deficiency in diabetic patients is the most important factor driving the insulin market globally. Rising prevalence of diabetes and extensive R&D activities are the other key factors boosting growth in the insulin market. No permanent cure has been invented for diabetes, thus the evolution of insulin therapy has emerged as an indispensible treatment therapy for type-1 diabetes patients.
The global and China insulin market is segmented based on source and mode of action. The insulin market by source is categorized as modern insulin and human insulin. The modern insulin segment is expected to grow at the fastest rate during the forecast period from 2013 to 2019, globally as well as in China. The insulin market by mode of action is segmented into rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Due to advantages over other derivatives, the long-acting derivatives segment is expected to grow rapidly during the forecast period. The segment held the largest share of 42.77% of the total market in 2012. It is expected to be the largest segment by the end of 2019. Rapid-acting insulin was the second largest segment in 2012. Other segments such as premixed, intermediate-acting and short-acting insulin derivatives are expected to lose market share during the forecast period. This is mainly due to low patient preference and lack of R&D in these segments. Pharmaceutical companies have concentrated their R&D strategies towards long-acting and rapid-acting derivatives development, which would boost market growth.
Browse Press Release of Global and China Insulin Market @ http://www.transparencymarketresearch.com/pressrelease/insulin-market.htm
The rapid-acting, long-acting and premixed derivatives segments are the most important segments in China. Growth in these segments is mainly attributed to rising population of type-1 diabetes and growing tendency of type-2 diabetes patients to use insulin as a therapeutic agent.
The insulin market in China is expected to grow steadily due to extensive R&D activities for the development of new insulin analogs and formulations that can be administered via different routes. Various products such as LY2605541 (Eli Lilly and Company), MK-1293 (Merck & Co., Inc.), NN1218 (Novo Nordisk A/S) and Afrezza (MannKind Corporation) are under pipeline studies and are expected to enter the market during the forecast period. Due to these new formulations, the market is likely to grow steadily during the forecast period.
Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=259
The insulin market is highly consolidated and dominated by select players operating on a global level such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi. In China, local and regional players such as Shanghai Fosun Pharmaceuticals Pvt. Ltd. and Tonghua Dongbao also contribute to the insulin market.
Related & Recently Published Reports by Transparency Market Research
Forensic Technologies Market: http://www.transparencymarketresearch.com/forensics-technology.html
Erectile Dysfunction Drugs Market: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
The global and China insulin market is segmented as follows:
Global and China Insulin Market, by Mode of Action
Global and China Insulin Market, by Source
Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Company Blog: http://www.tmrblog.com/
Erectile Dysfunction (ED) and Alternative Therapies for Impotence in 2015
(SI Newswire) Lots of men with erectile dysfunction (ED) have issues talking about their problem with their doctors. Because of this issue between patients and doctors, it is a strong curiosity in complementary, alternative medicine also known as CAM …
Read more on StreetInsider.com (subscription)
These conditions include kidney stones, overactive bladder, incontinence, urinary tract infection, bladder and kidney cancer, prostate cancer, erectile dysfunction and testicular cancer. The new clinic is located in Mercy Medical Tower, 2713 S. 74th St …
Read more on Times Record
The truth about erectile dysfunction
ED is a condition in which a man has trouble achieving or maintaining a satisfying erection during sexual activity. It is not just a one- or two-time occurrence, but something that happens on a regular basis and greatly interferes with a man's sexual …
Read more on Fox News
Official Fiat 500X teaser blue pill Viagra Pillola Blu Spot Ufficiale.
Video Rating: 4 / 5
KANUI : http://kanui.me/1o0LTFm Contato Profissional : Miticojovem@gmail.com Me siga no Twitter : https://twitter.com/miticojovems2 Facebook : http://www.fac…
Video Rating: 4 / 5
San Francisco, CA (PRWEB) February 21, 2014
With all eyes on the 2014 Sochi Olympics this month, SpaHub has taken an international focus by searching countries for the strangest spa treatments offered around the world. After much deliberation, the online spa directory shares its list of the top 10 weirdest spa treatments across the globe.
Here is the list of SpaHubs 10 Weirdest Spa Treatments from Around the World:
Port Washington, New York (PRWEB) October 09, 2014
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, comments on a lawsuit filed on September 29, 2014 against Eli Lilly over its testosterone replacement drug Axiron (Miller v. Lilly USA, Inc. et al, Case No. 2:2014cv06039 in the Third Circuit of New Jersey District Court). The federal lawsuit was filed on behalf of a man who took Axiron in September 2012 and subsequently suffered a heart attack on October 3, 2012. Lawsuit allegations include that Eli Lilly never warned about the increased risk of stroke and heart attack with Axiron and that, if the plaintiff’s doctor had been fully informed about Axirons potential dangers, he never would have prescribed the drug.
Lilly’s strategy for marketing Axiron involves describing symptoms of Low-T, which includes decreased sexual desire, erectile dysfunction (ED), fatigue, depressed mood, decreased strength, a decreasing need to shave, and osteoporosis, the suit alleges. Also according to the lawsuit, Low-T is a non-existent and unrecognized medical condition and the symptoms described are simply caused by normal aging or weight gain.
The lawsuit also points out that the U.S. Food and Drug Administration (FDA) has only approved testosterone products for hypogonadism, an endocrine disorder in which the body produces abnormally low levels of testosterone; they are not approved to treat Low-T as described by Eli Lilly. Despite this, the suit alleges that Lilly utilized a disease awareness campaign to notify men that they may be suffering from Low-T. According to the complaint, only six percent of men prescribed testosterone have been diagnosed with hypogonadism. The plaintiff is alleging the following: failure to warn, defective design, defective manufacturing, negligence, breach of implied warranty, breach of express warranty, fraud, and negligent misrepresentation.
Parker Waichman LLP notes that release of announcements by health regulators in the United States, Canada, and Europe, as well as research findings, have led to mounting lawsuits. For example, the FDA announced on January 31, 2014 that it began investigating the increased risk of stroke, heart attack, and death in testosterone product users. Similar investigations were launched by regulators in other countries, including the European Medicines Agency (EMA) (April 14, 2014) and Health Canada July 15, 2014. The reviews were sparked by two studies showing an increased risk of cardiovascular events with the use of testosterone replacement products. On November 6, 2013, a study published in the Journal of the American Medical Association (JAMA) found that older men were more likely to suffer from heart attack if they took testosterone. Another study published in PloS (Public Library of Science) on January 29, 2014 showed an increased risk of heart attack in older men and younger men with a pre-existing heart condition.
According to Parker Waichman LLP, testosterone lawsuits have also been on the rise ever since the drugs have been linked to an increased risk of stroke, There have been mounting safety concerns over the risks of testosterone replacement products, said Gary Falkowitz, Managing Attorney at Parker Waichman LLP. Although testosterone drugs are often marketed as a way to treat ‘Low-T,’ the FDA has only approved these products for men who have been diagnosed with a medical condition that adversely impacts testicular function. So-called Low-T is not a medical diagnosis.
If you or someone you know has used a Low T medication, you may have valuable legal rights. To discuss your case with one of our lawyers, please view our Testosterone lawsuit website or call 1-800-LAW-INFO (1-800-529-4636).